MANNHEIM, Germany & HORSHAM, Pa.--(BUSINESS WIRE)--BioGeneriX AG, a member of the ratiopharm Group of companies, and Neose Technologies, Inc. (NasdaqGM:NTEC) today announced positive data from two Phase I clinical studies of GlycoPEG-GCSF. GlycoPEG-GCSF is being co-developed by the companies for the treatment of neutropenia associated with myelosuppressive chemotherapy.
